Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:28:33 EDT Sun 12 May 2024
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - http://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.54.00·4.500.14.08+0.184.66,458.225,84817,1293.85  4.325  3.678.83  1.6319:28:31May 0915 min RT 2¢

Recent Trades - Last 10 of 17129
Time ETExPriceChangeVolume
19:28:31Q4.14830.2483500
17:46:32Q4.150.25200
17:33:00Q4.080.18284,800
17:07:39Q4.080.187,627
16:20:08Q4.020.121,000
16:20:00Q4.080.18481
16:04:55Q4.090.191
16:02:05Q4.080.18431
16:01:48Q4.080.18154
16:01:46Q4.080.18655

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-09 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
2024-05-09 08:30U:FATENews ReleaseFate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
2024-05-06 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
2024-05-03 16:30U:FATENews ReleaseFate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
2024-04-22 16:30U:FATENews ReleaseFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
2024-04-03 08:00U:FATENews ReleaseFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 08:45U:FATENews ReleaseFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
2024-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-01 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming March Investor Conferences
2024-02-26 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-15 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
2024-02-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:00U:FATENews ReleaseFate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
2023-12-13 17:00U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:01U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
2023-10-25 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
2023-08-31 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming September Investor Conferences
2023-08-08 16:01U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
2023-07-28 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results